[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 21 of about 21
3. Inoue T, Ohyama C, Horikawa Y, Togashi H, Matsuura S, Tsuchiya N, Satoh S, Sato K, Habuchi T, Saito S, Hoshi S, Arai Y, Kato T: [Active chemotherapy with gemcitabine, carboplatin and docetaxel for three patients with MVAC-resistant liver metastasis of urothelial carcinoma]. Hinyokika Kiyo; 2004 Apr;50(4):273-7
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Active chemotherapy with gemcitabine, carboplatin and docetaxel for three patients with MVAC-resistant liver metastasis of urothelial carcinoma].
  • We report three cases with methotrexate-vinblastin-adriamycin-cisplatin (MVAC) resistant multiple liver metastases of urothelial carcinoma that responded to combination chemotherapy consisting of gemcitabine plus carboplatin (GC) with additional docetaxel (GCD) as salvage chemotherapy.
  • Case 1: A 55-year-old man underwent left nephroureterectomy for ureteral cancer (TCC, G3, pT3pN1M0).
  • Three courses of GC followed by three courses of GCD were given via intra-hepatic arterial infusion for multiple liver metastases, which appeared after adjuvant high-dose MVAC therapy.
  • Case 2: A 46-year-old man underwent radical cystectomy for locally advanced bladder cancer (TCC G3 + adenocarcinoma. pT3pN0M0).
  • Two courses of GC followed by 2 courses of GCD systemic therapies were performed for multiple liver metastases, which appeared after adjuvant high-dose MVAC therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Deoxycytidine / analogs & derivatives. Drug Resistance, Neoplasm. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Urinary Bladder Neoplasms / drug therapy
  • [MeSH-minor] Aged. Carboplatin / administration & dosage. Cisplatin / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Kidney Neoplasms / drug therapy. Kidney Neoplasms / pathology. Male. Methotrexate / administration & dosage. Middle Aged. Taxoids / administration & dosage. Vinblastine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15188623.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; 5V9KLZ54CY / Vinblastine; 80168379AG / Doxorubicin; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; M-VAC protocol
  •  go-up   go-down


Advertisement
4. Ahmed K, Hoque R, El-Tawil S, Khan MS, George ML: Adenocarcinoma of the appendix presenting as bilateral ureteric obstruction. World J Surg Oncol; 2008;6:23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma of the appendix presenting as bilateral ureteric obstruction.
  • BACKGROUND: Adenocarcinoma of the vermiform appendix is a rare neoplasm of the gastrointestinal tract.
  • CASE PRESENTATION: We report a case of appendicular adenocarcinoma found unexpectedly in a 43 year old male who presented with urinary symptoms.
  • Histopathology revealed well differentiated adenocarcinoma with signet ring morphology with multiple lymph node involvement.
  • The patient was referred for chemotherapy where he received infusional 5 fluorouracil but died 7 months after surgery.
  • Every attempt should be made to make a precise diagnosis through all the available means to direct the treatment along correct lines.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Appendiceal Neoplasms / complications. Appendiceal Neoplasms / diagnosis. Ureteral Obstruction / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 2004 Jul;70(7):593-9 [15279181.001]
  • [Cites] Arch Surg. 1977 May;112(5):666-7 [856108.001]
  • [Cites] J La State Med Soc. 1991 Nov;143(11):29-31 [1753179.001]
  • [Cites] Tumori. 1993 Dec 31;79(6):447-9 [8171749.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):154-70 [8000994.001]
  • [Cites] Surg Today. 2005;35(2):168-71 [15674503.001]
  • [Cites] Urology. 2004 May;63(5):981-2 [15135001.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3307-12 [12115365.001]
  • [Cites] Hinyokika Kiyo. 2002 Jun;48(6):351-4 [12166235.001]
  • [Cites] Minerva Chir. 2002 Oct;57(5):597-605 [12370661.001]
  • [Cites] Minerva Chir. 2002 Oct;57(5):695-8 [12370673.001]
  • [Cites] Korean J Gastroenterol. 2004 Jan;43(1):29-34 [14745249.001]
  • [Cites] Eur J Gynaecol Oncol. 2004;25(1):113-5 [15053078.001]
  • [Cites] Rozhl Chir. 2005 Jan;84(1):33-6 [15813454.001]
  • (PMID = 18291037.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2277416
  •  go-up   go-down


5. Cabassa P, Morone M, Gatti E, Narbone M, Maroldi R: Gardner syndrome complicated with hydronephrosis. A case report. J Radiol Case Rep; 2010;4(3):19-23

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gardner syndrome is an autosomal dominant disease characterized by the presence of colonic polyposis, osteomas and soft tissue tumors.
  • We present a case of a man who was admitted for a relapse of adenocarcinoma of the rectum.
  • CT-staging showed multiple locations of desmoid tumors and osteomas, with final diagnosis of Gardner syndrome.
  • The follow-up CT, after surgery and chemotherapy, showed a relapse of the lesions with hydronephrosis due to ureteral compression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22470715.001).
  • [ISSN] 1943-0922
  • [Journal-full-title] Journal of radiology case reports
  • [ISO-abbreviation] J Radiol Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3303379
  • [Keywords] NOTNLM ; Gardner / computed tomography / desmoid tumors
  •  go-up   go-down


6. Hisamatsu H, Yamashita S: [A case of metastatic lung cancer with cavitation due to urothelial carcinoma]. Hinyokika Kiyo; 2010 May;56(5):269-72
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography revealed a left ureter tumor, which was removed by left nephroureterectomy in October 2003.
  • However, a part of the ureter could not be resected because of the adhesion that had occurred after a previous operation.
  • The patient was diagnosed with sigmoid colon cancer, and she underwent sigmoidectomy and resection of the remaining part of the ureter in August 2004.
  • Subsequently, transurethral resection was performed several times for bladder tumor.
  • The pathological diagnosis in February 2005 was pT2.
  • Cisplatin-based intra-arterial chemotherapy was performed because it was not possible to perform a cystectomy due to the poor performance status.
  • In March 2006, computed tomography of the chest revealed a mass shadow with a cavity in the left lower lung field.
  • Despite general chemotherapy, the patient's condition deteriorated, and the patient died 1 year later.
  • [MeSH-major] Carcinoma, Transitional Cell / radiography. Carcinoma, Transitional Cell / secondary. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Ureteral Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Aged. Female. Humans. Nephrectomy. Sigmoid Neoplasms / pathology. Tomography, X-Ray Computed. Ureter / surgery

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20519925.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


7. Morii A, Furuya Y, Fujiuchi Y, Akashi T, Ishizawa S, Fuse H: Urachal signet ring cell carcinoma. Int J Urol; 2007 Apr;14(4):360-1
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Urachal adenocarcinoma is a rare neoplasm associated with poor prognosis.
  • After undergoing radical cystectomy and intravenous chemotherapy, the patient developed bilateral hydronephroses as a result of bilateral ureteral metastases and bowel obstraction because of the Para-aortic lymphnode metastasis.
  • He has been alive for 5 years after three courses of chemotherapy and a bypass operation.

  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17470172.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


8. Benchekroun A, Nouini Y, Zannoud M, Kasmaoui el H, Jira H, el Alj HA: [Ureteral adenocarcinoma in men: a case report]. Ann Urol (Paris); 2003 Jun;37(3):131-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ureteral adenocarcinoma in men: a case report].
  • Adenocarcinoma of urethra is a rare tumour, which occurs more often in female than in male.
  • Because of scarcity of these tumours there is not therapeutic consensus.
  • The treatment is based on the tripod surgery, more or less mutilating, chemotherapy and radiotherapy associated or managed in a separate way.
  • We report the case of a young patient with adenocarcinoma of the posterior urethra treated by a protocol of radio-chemotherapy.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Urethral Neoplasms / pathology
  • [MeSH-minor] Adult. Cisplatin / administration & dosage. Combined Modality Therapy. Fluorouracil / administration & dosage. Humans. Male

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12872605.001).
  • [ISSN] 0003-4401
  • [Journal-full-title] Annales d'urologie
  • [ISO-abbreviation] Ann Urol (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


9. Romeu JP, Llopis JA, Baena JF, Abuomar A, Auladell AM, Encinas JJ: [Primary adenocarcinoma of a ureteral remnant stump after nephrectomy]. Actas Urol Esp; 2009 Jun;33(6):691-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary adenocarcinoma of a ureteral remnant stump after nephrectomy].
  • [Transliterated title] Adenocarcinoma primario en un remanente ureteral tras una nefrectomía simple.
  • There are no clinical guidelines for the management of primary ureteral adenocarcinoma.
  • METHODS: We report a case of adenocarcinoma affecting a ureteral stump in a patient who previously underwent a nephrectomy.
  • RESULTS: After the ureterectomy the pathologist diagnosed a ureteral adenocarcinoma.
  • CONCLUSIONS: Adenocarcinoma of the ureteral stump is a very rare malignancy.
  • Adjuvant chemotherapy can be employed with uncertain results.
  • [MeSH-major] Adenocarcinoma / etiology. Nephrectomy / adverse effects. Ureteral Neoplasms / etiology
  • [MeSH-minor] Decision Trees. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19711754.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 10
  •  go-up   go-down


10. Shibata N, Eto TA, Hotokezaka M, Iwamura T, Chijiiwa K: [An unresectable advanced gastric cancer with Virchow's metastasis, carcinomatous ascites and rectal stenosis, effectively managed with combined chemotherapy of biweekly paclitaxel and TS-1]. Gan To Kagaku Ryoho; 2005 Aug;32(8):1159-62
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An unresectable advanced gastric cancer with Virchow's metastasis, carcinomatous ascites and rectal stenosis, effectively managed with combined chemotherapy of biweekly paclitaxel and TS-1].
  • The biopsy specimen showed a poorly differentiated adenocarcinoma with signet-ring cells.
  • After placement of the bilateral ureteral stents, she was treated with combined chemotherapy of biweekly paclitaxel (120 mg/m2, day 1, day 15) and TS-1 (80 mg/day, days 1-14 with 2-weeks rest).
  • Subjective symptoms were relieved after one course of the chemotherapy.
  • After 3 courses, computed tomography showed markedly reduced supra-clavicular lymph node metastases and no ascites.
  • After the first course, the treatment was continued on an outpatient basis.
  • There were no adverse effects over grade 2 throughout six courses of the chemotherapy.
  • The biweekly paclitaxel and TS-1 chemotherapy may well be an effective treatment for advanced schirrhous gastric cancer with carcinomatous peritonitis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Signet Ring Cell / drug therapy. Stomach Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Ascites. Constriction, Pathologic. Drug Administration Schedule. Drug Combinations. Female. Humans. Lymphatic Metastasis. Oxonic Acid / administration & dosage. Paclitaxel / administration & dosage. Peritonitis / etiology. Pyridines / administration & dosage. Rectal Diseases / etiology. Tegafur / administration & dosage

  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16121920.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


11. Shimizu Y: Chemotherapy of advanced or recurrent cervical carcinoma with a consecutive low-dose cisplatin combined with bleomycin, vincristine, and mitomycin-C (consecutive low-dose BOMP). Gan To Kagaku Ryoho; 2000 May;27 Suppl 2:359-77
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy of advanced or recurrent cervical carcinoma with a consecutive low-dose cisplatin combined with bleomycin, vincristine, and mitomycin-C (consecutive low-dose BOMP).
  • There are many problems encountered in devising chemotherapy for patients with advanced or recurrent cervical carcinoma, in part because the vast majority of such patients have received prior radiation therapy with or without radical hysterectomy.
  • Prior radiation therapy not only impairs bone marrow reserve but also interferes with the vascular supply to the tumor bed and delivery of the drug.
  • In addition, many of the patients with advanced or recurrent cervical carcinoma have ureteral obstruction with impaired renal excretion of certain agents, thus limiting the tolerance to these agents.
  • The authors have designed a new chemotherapy protocol utilizing a consecutive low-dose cisplatin to overcome the above difficulties.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Bleomycin / administration & dosage. Carcinoma, Adenosquamous / drug therapy. Carcinoma, Adenosquamous / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Cisplatin / administration & dosage. Cisplatin / pharmacokinetics. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Middle Aged. Mitomycin / administration & dosage. Proportional Hazards Models. Survival Analysis. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10895181.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 50SG953SK6 / Mitomycin; 5J49Q6B70F / Vincristine; Q20Q21Q62J / Cisplatin; BOMP protocol
  • [Number-of-references] 59
  •  go-up   go-down


12. Huguet F, Cojocariu OM, Levy P, Lefranc JP, Darai E, Jannet D, Ansquer Y, Lhuillier PE, Benifla JL, Seince N, Touboul E: Preoperative concurrent radiation therapy and chemotherapy for bulky stage IB2, IIA, and IIB carcinoma of the uterine cervix with proximal parametrial invasion. Int J Radiat Oncol Biol Phys; 2008 Dec 1;72(5):1508-15
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative concurrent radiation therapy and chemotherapy for bulky stage IB2, IIA, and IIB carcinoma of the uterine cervix with proximal parametrial invasion.
  • Treatment consisted of preoperative external beam pelvic radiation therapy (EBRT) and concomitant chemotherapy (CT) during the first and fourth weeks of radiation combining 5-fluorouracil and cisplatin.
  • The pelvic radiation dose was 40.5 Gy over 4.5 weeks.
  • EBRT was followed by low-dose rate uterovaginal brachytherapy with a total dose of 20 Gy in 62 patients.
  • Thirty patients who had not received preoperative uterovaginal brachytherapy underwent postoperative low-dose-rate vaginal brachytherapy at a dose of 20 Gy.
  • Two severe ureteral complications requiring surgical intervention were observed.
  • [MeSH-major] Brachytherapy / methods. Hysterectomy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Combined Modality Therapy. Endometrium / pathology. Female. Humans. Lymph Node Excision. Lymphatic Metastasis. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Preoperative Care. Recurrence. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18676093.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Konishi K, Hasegawa N, Kaneko H, Iimura Y, Shoji Y, Kawabata M: [A case of stage IV breast cancer with large cancer ulcer responding to combination therapy of capecitabine and medroxyprogesterone acetate and cyclophosphamide]. Gan To Kagaku Ryoho; 2009 Sep;36(9):1525-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of stage IV breast cancer with large cancer ulcer responding to combination therapy of capecitabine and medroxyprogesterone acetate and cyclophosphamide].
  • Ureteral obstruction was treated by urinary tract catheter.
  • After improvement of renal failure, chemotherapy with 5-FU+epirubicin+cyclophosphamide (FEC) and docetaxel was performed.
  • For third-line chemotherapy, she was then treated with oral combination chemoendocrine therapy with capecitabine and medroxyprogesterone acetate.
  • After the combination chemoendocrine therapy, the local tumor was remarkably reduced.
  • No adverse reactions occurred with the combination chemoendocrine therapy.
  • It is suggested that this oral combination chemoendocrine therapy may be useful with consideration for treatment effectiveness and the quality of life of the patient.
  • [MeSH-major] Adenocarcinoma, Scirrhous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755825.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; 8N3DW7272P / Cyclophosphamide; C2QI4IOI2G / Medroxyprogesterone Acetate; EC 2.7.10.1 / Receptor, ErbB-2; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Hobdy EM, Ciesielski TE, Kummar S: Unusual sites of colorectal cancer metastasis. Clin Colorectal Cancer; 2003 May;3(1):54-7
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present 2 separate cases of adenocarcinoma of the colon with metastasis to the chin and the bladder, both of which are unusual sites of colorectal cancer metastasis.
  • Patient 1 is a 77-year-old man who was diagnosed with adenocarcinoma of the colon, American Joint Committee on Cancer (AJCC) T4 N0 M0 (stage II), and underwent a right hemicolectomy.
  • Fourteen months later he developed a firm 2.5-cm mass involving the chin.
  • Excisional biopsy revealed moderately differentiated adenocarcinoma, consistent with the known colon primary tumor.
  • Patient 2 is a 75-year-old man who was diagnosed with AJCC T3 N1 M0 (stage III) adenocarcinoma of the colon and underwent sigmoid colectomy.
  • Ten years later, he was found to have transitional cell carcinoma involving retroperitoneal nodes with no identifiable bladder or ureteral primary, for which he received chemotherapy.
  • Eighteen months following this diagnosis, he developed hematuria and was found to have metastatic colon adenocarcinoma involving the bladder.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology. Urinary Bladder Neoplasms / diagnosis. Urinary Bladder Neoplasms / secondary

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12777193.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Ruoppolo M, Pezzica E, Milesi R, Corti D, Mercurio P, Fragapane G: [Neuroendocrine small-cell bladder cancer: our experience]. Urologia; 2010 Oct-Dec;77 Suppl 17:64-71
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At the time of presentation 59% of patients have clinical stage >T2 and 56% show metastatic disease.
  • Local advanced disease was present in all the cases with stage >T2, metastatic disease in 1 case, lymph node involvement and ureteral bilateral obstruction in 2.
  • Platinum-based adjuvant chemotherapy was proposed but only two patients received the treatment.
  • CONCLUSIONS: In the absence of a prospective study, and because of the rarity of the disease, the best treatment for small-cell bladder cancer remains uncertain.
  • Neoadjuvant chemotherapy with platinum regimen plus aggressive surgical approach will be the treatment of choice.
  • The association of chemotherapy and radiotherapy should also be considered.
  • [MeSH-minor] Adenocarcinoma. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Combined Modality Therapy. Cystectomy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Disease Progression. Fatal Outcome. Gastrointestinal Hemorrhage / etiology. Hematuria / etiology. Humans. Intestinal Neoplasms / complications. Intestinal Neoplasms / secondary. Leukemia, Lymphocytic, Chronic, B-Cell. Liver Neoplasms / secondary. Lymph Node Excision. Male. Middle Aged. Neoplasms, Second Primary. Peritoneal Neoplasms / secondary. Prostatic Neoplasms. Stomach Neoplasms. Survival Rate

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21308678.001).
  • [ISSN] 1724-6075
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


16. de Pinieux G, Colin D, Vincent-Salomon A, Couturier J, Amsellem-Ouazana D, Beuzeboc P, Vieillefond A: Confrontation of immunohistochemistry and fluorescent in situ hybridization for the assessment of HER-2/ neu (c-erbb-2) status in urothelial carcinoma. Virchows Arch; 2004 May;444(5):415-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specific treatments targeted toward oncogenes expressed in cancer cells are currently under development.
  • Patients with urothelial carcinomas showing HER-2/ neu (human epidermal growth factor receptor 2) overexpression are candidates for such a specific treatment (trastuzumab).
  • However, to be effective, this therapeutic approach requires an extremely reliable evaluation of HER-2/ neu status in tumors.
  • Patients with urothelial carcinomas overexpressing HER-2/ neu using IHC are potential candidates for targeted chemotherapy.
  • [MeSH-major] Adenocarcinoma / metabolism. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Receptor, ErbB-2 / metabolism. Ureteral Neoplasms / metabolism. Urinary Bladder Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Lett. 1998 Apr 24;126(2):143-8 [9585059.001]
  • [Cites] J Pathol. 1993 Jan;169(1):35-42 [8094432.001]
  • [Cites] Cancer. 1992 Nov 15;70(10):2493-8 [1358427.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):69-72 [7819052.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1435-48 [9850170.001]
  • [Cites] Anticancer Res. 1994 May-Jun;14(3B):1317-24 [7915094.001]
  • [Cites] J Urol. 1996 Dec;156(6):2089-93 [8911396.001]
  • [Cites] Mod Pathol. 2000 Nov;13(11):1238-43 [11106082.001]
  • [Cites] Hum Pathol. 1995 Sep;26(9):970-8 [7672797.001]
  • [Cites] Acta Pathol Jpn. 1990 May;40(5):322-6 [2203226.001]
  • [Cites] Mod Pathol. 1995 Sep;8(7):758-64 [8539234.001]
  • [Cites] Pathol Int. 1997 Apr;47(4):209-16 [9103211.001]
  • [Cites] Int J Cancer. 2002 Dec 10;102(5):514-8 [12432555.001]
  • [Cites] Cancer Res. 1995 Jun 1;55(11):2422-30 [7757996.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):354-63 [11208826.001]
  • [Cites] Cancer. 2002 Sep 1;95(5):1009-15 [12209684.001]
  • [Cites] Br J Cancer. 1990 Nov;62(5):764-5 [1978784.001]
  • [Cites] Mod Pathol. 1992 Sep;5(5):531-6 [1364264.001]
  • [Cites] Eur Urol. 1991;20(3):238-42 [1688050.001]
  • [Cites] Acta Oncol. 2002;41(3):282-8 [12195748.001]
  • [Cites] J Urol. 1996 Jan;155(1):321-6 [7490879.001]
  • [Cites] Cancer Res. 1993 May 15;53(10 Suppl):2199-203 [8097962.001]
  • [Cites] Pathobiology. 1993;61(3-4):178-82 [8105802.001]
  • [Cites] Histol Histopathol. 2000 Jul;15(3):721-7 [10963116.001]
  • [Cites] Urology. 2000 May;55(5):679-83 [10792078.001]
  • [Cites] Urol Res. 1993 Jan;21(1):39-43 [8096102.001]
  • [Cites] Mod Pathol. 2000 Aug;13(8):866-73 [10955453.001]
  • [Cites] Histopathology. 1993 Apr;22(4):327-33 [8099896.001]
  • [Cites] J Urol. 1991 Feb;145(2):423-7 [1988741.001]
  • [Cites] Int J Oncol. 2002 Nov;21(5):981-7 [12370744.001]
  • (PMID = 15029496.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


17. Le Bouëdec G, Bailly C, De Lapasse C, Gimbergues P, Dauplat J: [Retained ovarian remnant carcinoma: a case report]. J Gynecol Obstet Biol Reprod (Paris); 2006 Dec;35(8 Pt 1):829-33
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ovarian remnant syndrome is defined as residual ovarian tissue non intentionally left in place by the surgeon during a bilateral salpingo-oophorectomy.
  • Patients present various symptoms usually including chronic pelvic pain, pelvic mass, bowel obstruction, hydronephrosis due to ureteral compression.
  • We report a case of adenocarcinoma arising in such an ovarian remnant revealed by vaginal bleeding 5 years after total abdominal hysterectomy and bilateral oophorectomy for uterine fibroids.
  • It was regarded as stage IIIc according to the FIGO classification because of common iliac lymph node involvement while there was no ascitis, no peritoneal nor omental implant but a unilateral hydronephrosis induced by extrinsec ureteral obstruction.
  • Complete cytoreductive surgery was achieved including partial bladder and lower ureteral resection with colpectomy, omentectomy, pelvic and para-aortic lymphadenectomy.
  • Paclitaxel-Platinum combination chemotherapy was given for nine cycles.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma / surgery. Hysterectomy / adverse effects. Ovarian Neoplasms / surgery. Ovariectomy / adverse effects
  • [MeSH-minor] Adult. Aged. Female. Humans. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Salpingostomy. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17151542.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 32
  •  go-up   go-down


18. Kadota K, Haba R, Ishikawa M, Kushida Y, Katsuki N, Hayashi T, Miyai Y, Bando K, Shiota A, Hata T: Uterine cervical carcinosarcoma with heterologous mesenchymal component: a case report and review of the literature. Arch Gynecol Obstet; 2009 Nov;280(5):839-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: A 61-year-old Japanese woman was admitted to the hospital for treatment of a ureteral stone.
  • A histopathological diagnosis of the cervical biopsy was a carcinosarcoma.
  • A total abdominal hysterectomy with bilateral salpingo-oophorectomy and pelvic lymphadenectomy was carried out upon a diagnosis of stage Ib1 cervical carcinosarcoma.
  • Microscopically, the cervical mass revealed a carcinosarcoma consisting of endometrioid adenocarcinoma and chondrosarcoma.
  • Postoperatively, the patient underwent radiation and chemotherapy.


19. Busby JE, Brown GA, Tamboli P, Kamat AM, Dinney CP, Grossman HB, Matin SF: Upper urinary tract tumors with nontransitional histology: a single-center experience. Urology; 2006 Mar;67(3):518-23
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We reviewed the patient records to collect data on tumor subtype, treatment, recurrence, and survival.
  • RESULTS: Sixteen patients (1.9% of our database of patients with upper urinary tract tumors) were identified; 12 had squamous cell carcinoma, 2 had adenocarcinoma, 1 had sarcomatoid carcinoma, and 1 had small cell carcinoma.
  • The tumors were located in the renal pelvis in 10 and the ureter in 6.
  • Of the 16 patients, 15 had been treated with nephrectomy or nephrouterectomy and 1 with chemotherapy and radiotherapy.
  • Ten patients received adjuvant chemotherapy.
  • The median follow-up was 30.1 months, the median overall survival time was 11.3 months, and 1-year survival rate was 46%.
  • The median recurrence-free survival time and 1-year recurrence-free survival rate were 5.8 months and 38%, respectively.
  • CONCLUSIONS: Primary nonurothelial carcinomas of the renal pelvis and ureter are rare.
  • Our analysis suggests a poor prognosis for most patients with these pathologic types, probably resulting from the advanced stage at diagnosis and poor responses to systemic therapy.
  • [MeSH-major] Carcinoma / pathology. Kidney Neoplasms / pathology. Kidney Pelvis. Ureteral Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527570.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA79449; United States / NCI NIH HHS / CA / CA91846
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


20. Jadvar H, Tatlidil R, Garcia AA, Conti PS: Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography. Clin Radiol; 2003 Mar;58(3):215-21
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of recurrent gastric malignancy with [F-18]-FDG positron emission tomography.
  • AIM: We retrospectively assessed the use of [(18)F] fluorodeoxyglucose positron emission tomography (FDG PET) in the evaluation of recurrent disease in patients with history of gastric malignancy.
  • Prior treatments included total (n = 4) or partial gastrectomy (n = 14) followed by chemotherapy alone (n = 7) or combined chemoradiation therapy (n = 2).
  • The interval between the most recent treatment and PET ranged from 3 months to 2 years.
  • RESULTS: PET was concordant with computed tomography (CT) in 12 patients (5 TP, 6 TN, 1 FN).
  • In one patient with negative imaging studies, an incidental finding of left obstructive uropathy was determined to be due to metastatic ureteral stricture.
  • Additional chemotherapy was initiated in these three patients (17% of total) based on PET localization of disease.
  • [MeSH-major] Adenocarcinoma / radionuclide imaging. Fluorodeoxyglucose F18. Leiomyosarcoma / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Stomach Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Retrospective Studies. Tomography, Emission-Computed / methods. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 The Royal College of Radiologists
  • [ErratumIn] Clin Radiol. 2003 Jul;58(7):570
  • (PMID = 12639527.001).
  • [ISSN] 0009-9260
  • [Journal-full-title] Clinical radiology
  • [ISO-abbreviation] Clin Radiol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down






Advertisement